Cadrenal Therapeutics, Inc. Common Stock Capital Reinvestment Ratio

Latest as of September 2022: 2.25x

Cadrenal Therapeutics, Inc. Common Stock capital reinvestment ratio. Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Capital Reinvestment Ratio of 2.25x as of September 2022, meaning it reinvests 2% of its operating cash flow ($1.01K) in capital expenditures ($2.28K). Check CVKD cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

2.25x

Capex / Operating Cash Flow

Operating Cash Flow

$1.01K

USD

Capital Expenditures

$2.28K

USD

Data as of

Sep 2022

Most recent filing

Cadrenal Therapeutics, Inc. Common Stock Capital Reinvestment Ratio by Year (None–None)

Cadrenal Therapeutics, Inc. Common Stock capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see CVKD cash generation efficiency.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow